Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

Read full text
Authors: Daniel Filip, Katerina Musilova Litzmanova, Androniki Michaelou, Filip Kledus, Ján Deván, Miroslav Boudný, Eva Hoferkova, Sonali Sharma, Václav Šeda, Pedro Faria Zeni, Marek Borský, Kvetoslava Matulova
+22 more Leos Kren, Jan Oppelt, Nicolas Blavet, Václav Hejret, Milan Urík, Andrea Marečková, Lisa M. Rimsza, Kateřina Kamarádová, David Belada, Alice Šýkorová, Heidi Mocikova, Marek Trneny, Zuzana Prouzová, Andrew G. Evans, Alexey Danilov, Heike Horn, German Ott, Philipp Staber, Jiri Mayer, Jonathan W. Friedberg, Andrea Janíková, Marek Mráz
Cited by: 1
References: 72

Abstract

Follicular lymphoma (FL) patients are at risk of disease transformation to aggressive high-grade lymphoma (tFL). While several genetic alterations have been implicated in tFL, the role of microenvironmental interactions and post-transcriptional regulation by non-coding RNAs remains poorly understood. We performed the first matched profiling of mRNAs and short non-coding RNAs (miRNAs) in paired FL and tFL samples (n = 11 pairs). This revealed differential expression of 1,075 mRNAs and 19 miRNAs, including repression of miR-29 family in tFL (miR-29a/b/c). Further analysis uncovered that MYC directly transcriptionally represses miR-29 in tFL, resulting in the upregulation of its target TRAF4. TRAF4 upregulation contributes to CD40 signaling being strongly activated in tFL and supports malignant B-cell proliferation. Notably, this increased CD40 pathway activity in 90% of tFL and contrasted with the reduced T-cell numbers in tFL niches. Thus, the MYC-miR-29-TRAF4 axis and increased CD40 signaling propensity may serve as tFL cells' adaptation to reduced numbers of CD40L+ T-cells. Moreover, lower levels of all miR-29s(a/b/c) were associated with shorter overall survival (OS) and progression-free survival in FL (n = 185), including in a multivariate analysis. Low miR-29c was also associated with shorter OS in a validation cohort (n = 92) from the first-line R-CHOP therapy clinical trial (SWOG S0016, NCT00006721).

Fields of Study & Subjects

Lymphoma Diagnosis and Treatment Immune Cell Function and Interaction Cutaneous lymphoproliferative disorders research

Publication details

Journal / source
Leukemia
Publisher
Springer Science and Business Media LLC
Volume
40
Issue
4
Pages
759–772
Publication date
19 February 2026
Language
EN